Redirecting specificity of T-cell populations for CD19 using the Sleeping Beauty system.

ABSTRACT: Genetic modification of clinical-grade T cells is undertaken to augment function, including redirecting specificity for desired antigen. We and others have introduced a chimeric antigen receptor (CAR) to enable T cells to recognize lineage-specific tumor antigen, such as CD19, and early-phase human trials are currently assessing safety and feasibility. However, a significant barrier to next-generation clinical studies is developing a suitable CAR expression vector capable of genetically modifying a broad population of T cells. Transduction of T cells is relatively efficient but it requires specialized manufacture of expensive clinical grade recombinant virus. Electrotransfer of naked DNA plasmid offers a cost-effective alternative approach, but the inefficiency of transgene integration man

SUBMITTER: Singh H 

PROVIDER: S-EPMC2424272 | biostudies-literature | 2008 Apr

REPOSITORIES: biostudies-literature